These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 28748389)

  • 1. Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years' experience in a single center.
    Koh JH; Myong JP; Yoo J; Lim YW; Lee J; Kwok SK; Park SH; Ju JH
    Osteoporos Int; 2017 Nov; 28(11):3251-3259. PubMed ID: 28748389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates.
    Sato H; Kondo N; Wada Y; Nakatsue T; Iguchi S; Fujisawa J; Kazama JJ; Kuroda T; Nakano M; Endo N; Narita I
    Osteoporos Int; 2016 Mar; 27(3):1217-1225. PubMed ID: 26519417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High and pointed type of femoral localized reaction frequently extends to complete and incomplete atypical femoral fracture in patients with autoimmune diseases on long-term glucocorticoids and bisphosphonates.
    Sato H; Kondo N; Nakatsue T; Wada Y; Fujisawa J; Kazama JJ; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I
    Osteoporos Int; 2017 Aug; 28(8):2367-2376. PubMed ID: 28409215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical Femoral Fracture in Rheumatoid Arthritis Patients Treated With Bisphosphonates: A Nested Case-Control Study.
    Koh JH; Myong JP; Jung SM; Lee J; Kwok SK; Park SH; Ju JH
    Arthritis Rheumatol; 2016 Jan; 68(1):77-82. PubMed ID: 26360133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence, risk factors, and fracture healing of atypical femoral fractures: a multicenter case-control study.
    Lim SJ; Yeo I; Yoon PW; Yoo JJ; Rhyu KH; Han SB; Lee WS; Song JH; Min BW; Park YS
    Osteoporos Int; 2018 Nov; 29(11):2427-2435. PubMed ID: 30039251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical femur fracture during bisphosphonate drug holiday: a case series.
    Lovy AJ; Koehler SM; Keswani A; Joseph D; Hasija R; Ghillani R
    Osteoporos Int; 2015 Jun; 26(6):1755-8. PubMed ID: 25832177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of bone microarchitecture in postmenopausal women on long-term bisphosphonate therapy with atypical fractures of the femur.
    Zanchetta MB; Diehl M; Buttazzoni M; Galich A; Silveira F; Bogado CE; Zanchetta JR
    J Bone Miner Res; 2014 Apr; 29(4):999-1004. PubMed ID: 24115250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan.
    Sato H; Kondo N; Wakamatsu A; Kobayashi D; Nakatsue T; Wada Y; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I
    Rheumatol Int; 2019 Oct; 39(10):1803-1810. PubMed ID: 31385078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.
    Shane E; Burr D; Abrahamsen B; Adler RA; Brown TD; Cheung AM; Cosman F; Curtis JR; Dell R; Dempster DW; Ebeling PR; Einhorn TA; Genant HK; Geusens P; Klaushofer K; Lane JM; McKiernan F; McKinney R; Ng A; Nieves J; O'Keefe R; Papapoulos S; Howe TS; van der Meulen MC; Weinstein RS; Whyte MP
    J Bone Miner Res; 2014 Jan; 29(1):1-23. PubMed ID: 23712442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lateral Cortical Thickening and Bone Heterogeneity of the Subtrochanteric Femur Measured With Quantitative CT as Indicators for Early Detection of Atypical Femoral Fractures in Long-Term Bisphosphonate Users.
    Lee SH; Lee YH; Suh JS
    AJR Am J Roentgenol; 2017 Oct; 209(4):867-873. PubMed ID: 28796551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone cross-sectional geometry is not associated with atypical femoral fractures in Asian female chronic bisphosphonate users.
    Chou AC; Ng AC; Png MA; Chua DT; Ng DC; Howe TS; Koh JS
    Bone; 2015 Oct; 79():170-5. PubMed ID: 26067179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of bisphosphonate therapy on bone geometry, volumetric bone density and bone strength of femoral shaft in postmenopausal women with rheumatoid arthritis.
    Meinen R; Galli-Lysak I; Villiger PM; Aeberli D
    BMC Musculoskelet Disord; 2016 Aug; 17():324. PubMed ID: 27491286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management.
    Black DM; Abrahamsen B; Bouxsein ML; Einhorn T; Napoli N
    Endocr Rev; 2019 Apr; 40(2):333-368. PubMed ID: 30169557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years.
    Lo JC; Neugebauer RS; Ettinger B; Chandra M; Hui RL; Ott SM; Grimsrud CD; Izano MA
    BMC Musculoskelet Disord; 2020 Dec; 21(1):801. PubMed ID: 33272248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical femur fractures.
    Borrelli J; Lane J; Bukata S; Egol KA; Takemoto R; Slobogean G; Morshed S
    J Orthop Trauma; 2014; 28 Suppl 1():S36-42. PubMed ID: 24476604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.
    Mignot MA; Taisne N; Legroux I; Cortet B; Paccou J
    Osteoporos Int; 2017 Dec; 28(12):3431-3438. PubMed ID: 28875236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and medical management of bisphosphonate-associated atypical femoral fractures in a major trauma centre: a retrospective observational study.
    Eisenstein N; Kasavkar G; Bhavsar D; Khan FS; Paskins Z
    BMC Musculoskelet Disord; 2017 Jan; 18(1):29. PubMed ID: 28114975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates and the risk of atypical femur fractures.
    Black DM; Condra K; Adams AL; Eastell R
    Bone; 2022 Mar; 156():116297. PubMed ID: 34920168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur.
    Greenspan SL; Vujevich K; Britton C; Herradura A; Gruen G; Tarkin I; Siska P; Hamlin B; Perera S
    Osteoporos Int; 2018 Feb; 29(2):501-506. PubMed ID: 29085957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate Use and Risk of Atypical Femoral Fractures: A Danish Case-Cohort Study With Blinded Radiographic Review.
    Bauer DC; Black DM; Dell R; Fan B; Smith CD; Ernst MT; Jurik AG; Frøkjær JB; Boesen M; Vittinghoff E; Abrahamsen B
    J Clin Endocrinol Metab; 2024 Oct; 109(11):e2141-e2150. PubMed ID: 38198798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.